Thera-SAbDab

MOGAMULIZUMAB

>   Structural Summary
TherapeuticMogamulizumab
TargetCCR4
Heavy ChainEVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS
Light ChainDVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedAmgen, Bristol-Myers Squibb, Kagoshima University Dental School, Kyowa Hakko, Kyowa Hakko Kirin, Ono Pharmaceutical
Conditions ApprovedAdult T-cell leukaemia-lymphoma, Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, Mycosis fungoides, Sezary syndrome, Mycosis fungoides
Conditions ActiveSpinal cord disorders
Conditions DiscontinuedNon-small cell lung cancer, Asthma, Hypersensitivity, Solid tumours
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy